

Resource Summary Report

Generated by [Kravitz](#) on Sep 10, 2026

BioVacSafe

RRID:SCR_003745

Type: Tool

Proper Citation

BioVacSafe (RRID:SCR_003745)

Resource Information

URL: <http://www.biovacsafe.eu/>

Proper Citation: BioVacSafe (RRID:SCR_003745)

Description: Project focused on developing cutting edge tools to speed up and improve the testing and monitoring of vaccine safety, both before and after release to the market. The three specific objectives of the project are: * the characterization of early inflammation induced by vaccines currently on the market and the identification and validation of biomarkers of early inflammation and allergic responses; * the identification and validation of early biomarkers of autoimmunity and their use to help identifying population at risk of developing autoimmunity; * the analysis of the incidence and epidemiology of autoimmune disease in the general population and the link to genetic background or previous events in the life of patients, including severe effects, such as anaphylactic shock.

Abbreviations: BioVacSafe

Synonyms: Biomarkers for Enhanced Vaccine Safety, Biovacsafe.eu, Biomarkers for enhanced vaccines immunosafety, Biomarkers for Enhanced Vaccine ImmunoSafety, BioVacSafe Project, BioVacSafe - Biomarkers for enhanced vaccines immunosafety

Resource Type: consortium, data or information resource, organization portal, portal

Keywords: safety, biomarker, consortium, clinical trial, inflammation, vaccine, infection, immunosafety, efficacy, autoimmunity, drug development, drug, test, monitor

Funding: Innovative Medicines Initiative 115308

Resource Name: BioVacSafe

Resource ID: SCR_003745

Alternate IDs: nlx_157978

Record Creation Time: 20220129T080220+0000

Ratings and Alerts

No rating or validation information has been found for BioVacSafe.

No alerts have been found for BioVacSafe.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [Kravitz](#).

Pagnon A, et al. (2024) Next generation yellow fever vaccine induces an equivalent immune and transcriptomic profile to the current vaccine: observations from a phase I randomised clinical trial. *EBioMedicine*, 108, 105332.

Mantel N, et al. (2024) Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination. *Journal of virology*, 98(5), e0151623.

Kennedy RB, et al. (2020) Current Challenges in Vaccinology. *Frontiers in immunology*, 11, 1181.

Tregoning JS, et al. (2020) Pregnancy has a minimal impact on the acute transcriptional signature to vaccination. *NPJ vaccines*, 5, 29.

Weiner J, et al. (2019) Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium. *Scientific reports*, 9(1), 20362.

Guo ZP, et al. (2018) Changes in lipid metabolism convey acid tolerance in *Saccharomyces cerevisiae*. *Biotechnology for biofuels*, 11, 297.

Muturi-Kioi V, et al. (2016) Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review. *PloS one*, 11(8), e0157385.